LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Nocardial Infection in the Early Period after Kidney Transplantation.

    Gupta, Sudeendra / Abdulbaki, Ammar / El Hajj, Sandra / Nusair, Ahmad / Mooty, Mohamad / Attallah, Nizar

    Case reports in infectious diseases

    2022  Volume 2022, Page(s) 2252825

    Abstract: Patients with solid organ transplant have weaker immune system and can develop opportunistic infections. Prophylactic antimicrobials can help lower that risk but do not prevent it completely. High index of suspicion increases the chance of diagnosing ... ...

    Abstract Patients with solid organ transplant have weaker immune system and can develop opportunistic infections. Prophylactic antimicrobials can help lower that risk but do not prevent it completely. High index of suspicion increases the chance of diagnosing rare opportunistic infections in immunocompromised patients and helps early and effective treatment. We present a unique case of a patient who developed pneumonia from
    Language English
    Publishing date 2022-08-12
    Publishing country Egypt
    Document type Case Reports
    ZDB-ID 2627642-2
    ISSN 2090-6633 ; 2090-6625
    ISSN (online) 2090-6633
    ISSN 2090-6625
    DOI 10.1155/2022/2252825
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy.

    Mallah, Saad I / Atallah, Bassam / Moustafa, Fathi / Naguib, Michael / El Hajj, Sandra / Bader, Feras / Mehra, Mandeep R

    Progress in cardiovascular diseases

    2020  Volume 63, Issue 3, Page(s) 194–209

    Abstract: Cardiac allograft vasculopathy (CAV)-mediated by a heterogeneous myriad of immune and non-immune factors, which contribute to the progressive and diffuse thickening of the arterial allograft's tunica intima in one distinct form of CAV, and the build-up ... ...

    Abstract Cardiac allograft vasculopathy (CAV)-mediated by a heterogeneous myriad of immune and non-immune factors, which contribute to the progressive and diffuse thickening of the arterial allograft's tunica intima in one distinct form of CAV, and the build-up of plaque in another-is a major limiting factor of long-term survival post heart transplantation. Information on the optimal pharmacotherapeutic approaches for the prevention and management of CAV is conflicting, scattered, and inconsistent, with numerous recent studies adding to the literature. In this paper, we present a go-to clinical resource with the most updated and comprehensive information on the topic. Immunosuppressant therapy remains a staple, with mTOR inhibitors and mycophenolate mofetil (MMF) showing direct correlation with CAV prevention. More data is now available with calcineurin inhibitor (CNI) minimizing or sparing regimens. More novel approaches are being investigated for the roles of monoclonal antibodies, anti-thymocyte globulin, and bortezomib in preventing or delaying CAV. On the other hand, statins' established efficacy is attributed to lipid-lowering and lipid-independent immunomodulatory effects, with early initiation associated with improved outcomes. The choice of statin is dependent on drug-drug interactions. Other aiding approaches for the prevention of CAV include antioxidant vitamins, aspirin, vasodilators, folate therapy, and, most pertinently, cytomegalovirus prophylaxis. Larger clinical trials are needed before these options are institutionalised. For management of established CAV, early initiation of augmented immunosuppressive therapies may be effective, as well as CNI conversion to mTOR inhibitors with or without standard MMF and azathioprine therapy. Risk of acute rejection needs to be monitored during conversion. Finally, preclinical investigations highlight novel potential therapies for CAV prevention and attenuation, however robust clinical trials are needed to test their efficacy and safety.
    MeSH term(s) Animals ; Heart Diseases/epidemiology ; Heart Diseases/immunology ; Heart Diseases/prevention & control ; Heart Transplantation/adverse effects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Risk Factors ; Treatment Outcome
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Immunosuppressive Agents
    Language English
    Publishing date 2020-03-20
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 209312-1
    ISSN 1873-1740 ; 1532-8643 ; 0033-0620
    ISSN (online) 1873-1740 ; 1532-8643
    ISSN 0033-0620
    DOI 10.1016/j.pcad.2020.03.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 229: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Generic immunosuppression in transplantation: current evidence and controversial issues.

    El Hajj, Sandra / Kim, Miae / Phillips, Karen / Gabardi, Steven

    Expert review of clinical immunology

    2015  Volume 11, Issue 5, Page(s) 659–672

    Abstract: The overall success of organ transplantation in the 21st century has been predicated, in part, on the use of newer, more potent, and selective immunosuppressive agents. However, the high cost of lifelong immunosuppression represents a financial burden ... ...

    Abstract The overall success of organ transplantation in the 21st century has been predicated, in part, on the use of newer, more potent, and selective immunosuppressive agents. However, the high cost of lifelong immunosuppression represents a financial burden for many patients. In the past 15 years, regulatory agencies in Europe and America have approved several generic immunosuppressants. One concern is whether the conversion between innovator and generic immunosuppressants will prove to be problematic. This manuscript aims to compare and contrast the bioequivalence requirements among regulatory authorities in the USA, Europe, and Canada, evaluate published studies of generic immunosuppressants in transplant recipients, summarize consensus statements made by transplant organizations and discuss how to engage patients in discussion regarding the choice between innovator and generic immunosuppressants.
    MeSH term(s) Animals ; Canada ; Consensus ; Cost-Benefit Analysis ; Drug and Narcotic Control ; Drugs, Generic/economics ; Drugs, Generic/pharmacokinetics ; Drugs, Generic/therapeutic use ; Europe ; Graft Rejection/prevention & control ; Humans ; Immunosuppression ; Immunosuppressive Agents/economics ; Immunosuppressive Agents/pharmacokinetics ; Immunosuppressive Agents/therapeutic use ; Organ Transplantation ; Therapeutic Equivalency ; Therapies, Investigational ; United States
    Chemical Substances Drugs, Generic ; Immunosuppressive Agents
    Language English
    Publishing date 2015-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1586/1744666X.2015.1026895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6661: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top